| Company Name: |
ShangHai Caerulum Pharma Discovery Co., Ltd.
|
| Tel: |
18149758185 18149758185 |
| Email: |
sales-cpd@caerulumpharma.com |
| Products Intro: |
Product Name:RORγt Inverse agonist 6
CAS:1887161-80-9
Purity:98% Package:10mg;100mg;1g;10g;100g;1kg Remarks:1g
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Email: |
sales@dcchemicals.com |
| Products Intro: |
Product Name:RORγt Inverse agonist 6
CAS:1887161-80-9
Purity:98% HPLC Package:100mg，250mg，1g
|
RORγt Inverse agonist 6 manufacturers
|
| | RORγt Inverse agonist 6 Basic information |
| Product Name: | RORγt Inverse agonist 6 | | Synonyms: | RORγt Inverse agonist 6;Inhibitor,ROR,RORγt Inverse agonist-6,inhibit,RAR-related orphan receptor,RORγt Inverse agonist 6,RORγt Inverse agonist6;2,4-Morpholinedicarboxamide, N2-(3-chloro-4-cyanophenyl)-N4-[3-(cyclopropylmethyl)-1,2,3,4-tetrahydro-1-(1-methylethyl)-2,4-dioxo-6-quinazolinyl]-, (2R)-;RORγt Inverse agonist 6, 10 mM in DMSO | | CAS: | 1887161-80-9 | | MF: | C28H29ClN6O5 | | MW: | 565.02 | | EINECS: | | | Product Categories: | | | Mol File: | 1887161-80-9.mol |  |
| | RORγt Inverse agonist 6 Chemical Properties |
| density | 1.46±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (88.49 mM; Need ultrasonic) | | pka | 11.82±0.70(Predicted) | | form | Solid | | color | White to off-white |
| | RORγt Inverse agonist 6 Usage And Synthesis |
| Uses | RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo[1]. | | Biological Activity | RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo[1].
RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in a mouse pharmacodynamics model[1].RORγt Inverse agonist 6 (compound 43) exhibits improved drug exposure (mouse AUC: 1289 ng?h/mL at 1 mg/kg, po)[1].RORγt Inverse agonist 6 (compound 43, 30 mg/kg, po, b.i.d) inhibits the expression level of IL-17A by 59% compared to the vehicle after the oral administration at the tested dose[1]. | | in vivo | RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in a mouse pharmacodynamics model[1].
RORγt Inverse agonist 6 (compound 43) exhibits improved drug exposure (mouse AUC: 1289 ng?h/mL at 1 mg/kg, po)[1].
RORγt Inverse agonist 6 (compound 43, 30 mg/kg, po, b.i.d) inhibits the expression level of IL-17A by 59% compared to the vehicle after the oral administration at the tested dose[1]. | Animal Model: | Mice[1]. | | Dosage: | 30 mg/kg. | | Administration: | Orally twice: at 30 min before and 8 h after IL-23 administration. | | Result: | Inhibited the expression level of IL-17A by 59% compared to the vehicle after the oral administration at the tested dose.
|
| | References | [1]. Sato A, et al. Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists. ChemMedChem. 2019 Oct 28. |
| | RORγt Inverse agonist 6 Preparation Products And Raw materials |
|